{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:23:38Z","timestamp":1791829418295,"version":"4.3.4"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"35","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This systematic review and meta-analysis included 34 studies encompassing 983 438 adult cancer survivors and evaluated the performance of both general-population and cancer-specific cardiovascular risk\u2013prediction models across vascular events, cancer therapy-related cardiac dysfunction or heart failure, arrhythmias, and composite cardiovascular event outcomes. In total, 27 unique risk scores were assessed.<\/jats:p>\n                  <jats:p>Approximately one-third of model\u2013outcome evaluations demonstrated acceptable-to-good discrimination, defined as an area under the curve of \u22650.70. Among general-population models, four risk scores demonstrated acceptable-to-good discrimination for vascular events, three models were acceptable for CTRCD\/heart failure, and two models for arrhythmias. The New Zealand CVD score was the only composite outcome model with an AUC \u22650.70. Cancer-specific scores, such as HFA-ICOS and the Ezaz score, showed high specificity for selected outcomes and may support rule-in decisions, although their lower sensitivity limits use for ruling out risk of CTRCD\/heart failure. In our subgroup analysis, model performance varied by cancer type, with more consistent discrimination in breast cancer cohorts and substantially poorer performance in survivors of haematologic malignancies, indicating limited transportability across cancer populations.<\/jats:p>\n                  <jats:p>In summary, these findings provide a comprehensive overview of available cardiovascular risk\u2013prediction tools and may assist clinicians in selecting appropriate models for primary cardiovascular prevention in cancer survivors while highlighting the need for exposure-aware, externally validated models tailored to specific cancer populations.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag562","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:34:32Z","timestamp":1784028872000},"page":"4941-4956","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular risk\u2013prediction models in cancer survivors: a meta-analysis"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-0858","authenticated-orcid":false,"given":"Sina","family":"Kazemian","sequence":"first","affiliation":[{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9231-3674","authenticated-orcid":false,"given":"Azin","family":"Vakilpour","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Hospital of the University of Pennsylvania , 3400 Spruce Street, Philadelphia, PA 19104 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-9266","authenticated-orcid":false,"given":"Marielle","family":"Scherrer-Crosbie","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Hospital of the University of Pennsylvania , 3400 Spruce Street, Philadelphia, PA 19104 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026091519575917500_ehag562-B1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3322\/caac.70011","article-title":"Cancer treatment and survivorship statistics, 2025","volume":"75","author":"NS","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026091519575917500_ehag562-B2","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"2026091519575917500_ehag562-B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103274","article-title":"Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis","volume":"84","author":"Li","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026091519575917500_ehag562-B4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41569-024-01017-x","article-title":"Cardiovascular disease and cancer: shared risk factors and mechanisms","volume":"21","author":"Wilcox","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026091519575917500_ehag562-B5","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026091519575917500_ehag562-B6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/jco.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026091519575917500_ehag562-B7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaccao.2024.05.015","article-title":"Predictive performance of cardiovascular risk scores in cancer survivors from the UK biobank","volume":"6","author":"McCracken","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026091519575917500_ehag562-B8","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1002\/ehf2.14879","article-title":"Predicting cardiovascular events with fluoropyrimidine chemotherapy using a standard cardiovascular risk calculator","volume":"11","author":"Abiodun","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026091519575917500_ehag562-B9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11764-023-01379-0","article-title":"Performance of the pooled cohort equations in cancer survivors: the atherosclerosis risk in communities study","volume":"18","author":"Polter","year":"2024","journal-title":"J Cancer Surviv"},{"key":"2026091519575917500_ehag562-B10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00277-023-05556-0","article-title":"The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib","volume":"103","author":"Mulas","year":"2024","journal-title":"Ann Hematol"},{"key":"2026091519575917500_ehag562-B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100660","article-title":"External validation of cardiac disease, hypertension, and logarithmic left anterior descending coronary artery radiation dose (CHyLL) for predicting major adverse cardiac events after lung cancer radiotherapy","volume":"42","author":"Tjong","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026091519575917500_ehag562-B12","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1093\/eurheartj\/ehz460","article-title":"Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study","volume":"40","author":"Abdel-Qadir","year":"2019","journal-title":"Eur Heart J"},{"key":"2026091519575917500_ehag562-B13","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026091519575917500_ehag562-B14","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/jco.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026091519575917500_ehag562-B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026091519575917500_ehag562-B16","author":"Kazemian"},{"key":"2026091519575917500_ehag562-B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/m18-1376","article-title":"PROBAST: a tool to assess the risk of bias and applicability of prediction model studies","volume":"170","author":"Wolff","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026091519575917500_ehag562-B18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"2026091519575917500_ehag562-B19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaccao.2024.12.007","article-title":"Risk stratification for trastuzumab-induced cardiac dysfunction and potential implications for surveillance","volume":"7","author":"Ali","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026091519575917500_ehag562-B20","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.3390\/cancers17142353","article-title":"Validation of the HFA-ICOS score for carfilzomib-induced cardiotoxicity in multiple myeloma: a real-life perspective study","volume":"17","author":"Astarita","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026091519575917500_ehag562-B21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/eurheartj\/ehae496","article-title":"Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score","volume":"46","author":"Rivero-Santana","year":"2025","journal-title":"Eur Heart J"},{"key":"2026091519575917500_ehag562-B22","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/ehf2.15165","article-title":"Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: are women and men different?","volume":"12","author":"Madaudo","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026091519575917500_ehag562-B23","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10840-025-01990-4","article-title":"Developing a simple clinical risk score for ibrutinib-associated atrial fibrillation","volume":"68","author":"Jacobson","year":"2025","journal-title":"J Interv Card Electrophysiol"},{"key":"2026091519575917500_ehag562-B24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40959-024-00267-5","article-title":"Comparison of heart failure risk assessment tools among cancer survivors","volume":"10","author":"Soh","year":"2024","journal-title":"Cardiooncology"},{"key":"2026091519575917500_ehag562-B25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.2459\/jcm.0000000000001589","article-title":"The added value of the HFA\/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer","volume":"25","author":"Di Lisi","year":"2024","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026091519575917500_ehag562-B26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40959-024-00245-x","article-title":"Cardiovascular events in CML patients treated with nilotinib: validation of the HFA-ICOS baseline risk score","volume":"10","author":"Fernando","year":"2024","journal-title":"Cardiooncology"},{"key":"2026091519575917500_ehag562-B27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/s0140-6736(22)02405-9","article-title":"Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study","volume":"401","author":"Tawfiq","year":"2023","journal-title":"Lancet"},{"key":"2026091519575917500_ehag562-B28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041278","article-title":"Heart Failure Association-International Cardio-Oncology Society risk score validation in HER2-positive Breast Cancer","volume":"12","author":"Cronin","year":"2023","journal-title":"J Clin Med"},{"key":"2026091519575917500_ehag562-B29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/10428194.2022.2140289","article-title":"External validation of a heart failure risk score in patients with acute myeloid leukemia","volume":"64","author":"Doukas","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"2026091519575917500_ehag562-B30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/coc.0000000000000904","article-title":"Cardiovascular diseases following Breast Cancer: towards a case-by-case assessment through a prediction risk score model in 943 patients","volume":"45","author":"Mery","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"2026091519575917500_ehag562-B31","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.3399\/bjgp.2022.0088","article-title":"Cancer history as a predictor in cardiovascular risk scores: a primary care cohort study","volume":"73","author":"Strongman","year":"2023","journal-title":"Br J Gen Pract"},{"key":"2026091519575917500_ehag562-B32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijcard.2022.06.063","article-title":"Predictability of cardiotoxicity: experience of a Belgian cardio-oncology clinic","volume":"363","author":"Jacobs","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026091519575917500_ehag562-B33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/jcm11030847","article-title":"Evaluation of risk prediction models to identify cancer therapeutics related cardiac dysfunction in women with HER2+ Breast Cancer","volume":"11","author":"Suntheralingam","year":"2022","journal-title":"J Clin Med"},{"key":"2026091519575917500_ehag562-B34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13058-021-01469-w","article-title":"Modeling risks of cardiovascular and cancer mortality following a diagnosis of loco-regional breast cancer","volume":"23","author":"Leoce","year":"2021","journal-title":"Breast Cancer Res"},{"key":"2026091519575917500_ehag562-B35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","article-title":"Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer","volume":"188","author":"Battisti","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2026091519575917500_ehag562-B36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes","volume":"100","author":"Archibald","year":"2021","journal-title":"Ann Hematol"},{"key":"2026091519575917500_ehag562-B37","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the systematic coronary risk evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"key":"2026091519575917500_ehag562-B38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/ejh.13234","article-title":"Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification","volume":"102","author":"Ferraro","year":"2019","journal-title":"Eur J Haematol"},{"key":"2026091519575917500_ehag562-B39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40959-019-0043-8","article-title":"Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study","volume":"5","author":"Moey","year":"2019","journal-title":"Cardiooncology"},{"key":"2026091519575917500_ehag562-B40","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3747\/co.24.3349","article-title":"Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population","volume":"24","author":"Rushton","year":"2017","journal-title":"Curr Oncol"},{"key":"2026091519575917500_ehag562-B41","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.3747\/co.24.3684","article-title":"The framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population","volume":"24","author":"Law","year":"2017","journal-title":"Curr Oncol"},{"key":"2026091519575917500_ehag562-B42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2017.10.007","article-title":"Comparison of CHA(2)DS(2)-VASc, CHADS(2) and HATCH scores for the prediction of new-onset atrial fibrillation in cancer patients: a nationwide cohort study of 760,339 study participants with competing risk analysis","volume":"266","author":"Hu","year":"2017","journal-title":"Atherosclerosis"},{"key":"2026091519575917500_ehag562-B43","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/leu.2014.342","article-title":"Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia","volume":"29","author":"Rea","year":"2015","journal-title":"Leukemia"},{"key":"2026091519575917500_ehag562-B44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol"},{"key":"2026091519575917500_ehag562-B45","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.15420\/ecr.2022.63","article-title":"The 2022 European Society of Cardiology Cardio-oncology guidelines in focus","volume":"18","author":"Gent","year":"2023","journal-title":"Eur Cardiol"},{"key":"2026091519575917500_ehag562-B46","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"2026091519575917500_ehag562-B47","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1038\/s41375-024-02413-5","article-title":"Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database","volume":"38","author":"Alexandre","year":"2024","journal-title":"Leukemia"},{"key":"2026091519575917500_ehag562-B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2024.06.006","article-title":"Cardiovascular considerations after Cancer therapy: gaps in evidence and JACC: cardioOncology expert panel recommendations","volume":"7","author":"Blaes","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026091519575917500_ehag562-B49","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/life14040524","article-title":"Applied cardio-oncology in hematological malignancies: a narrative review","volume":"14","author":"Mandala","year":"2024","journal-title":"Life (Basel)"},{"key":"2026091519575917500_ehag562-B50","doi-asserted-by":"publisher","DOI":"10.1002\/sim.70254","article-title":"Determining the optimal sequence of multiple tests","volume":"44","author":"B\u00f6ttcher","year":"2025","journal-title":"Stat Med"},{"key":"2026091519575917500_ehag562-B51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7594","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Collins","year":"2015","journal-title":"BMJ"},{"key":"2026091519575917500_ehag562-B52","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.tcm.2026.01.006","article-title":"Harnessing artificial intelligence for cardio-oncology:towards a new future of cardiovascular care for the Cancer patient","volume":"36","author":"Ma","year":"2026","journal-title":"Trends Cardiovasc Med"},{"key":"2026091519575917500_ehag562-B53","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/ehjdh\/ztad031","article-title":"Artificial intelligence modelling to assess the risk of cardiovascular disease in oncology patients","volume":"4","author":"Al-Droubi","year":"2023","journal-title":"Eur Heart J Digit Health"},{"key":"2026091519575917500_ehag562-B54","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1038\/s41467-024-45733-x","article-title":"Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms","volume":"15","author":"Yagi","year":"2024","journal-title":"Nat Commun"},{"key":"2026091519575917500_ehag562-B55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/ehjdh\/ztad058","article-title":"Improving cardiovascular risk prediction through machine learning modelling of irregularly repeated electronic health records","volume":"5","author":"Li","year":"2024","journal-title":"Eur Heart J Digit Health"},{"key":"2026091519575917500_ehag562-B56","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.124.036946","article-title":"Harnessing electronic health records and artificial intelligence for enhanced cardiovascular risk prediction: a comprehensive review","volume":"14","author":"Tsai","year":"2025","journal-title":"J Am Heart Assoc"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/35\/4941\/70259779\/ehag562.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/35\/4941\/70259779\/ehag562.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:58:03Z","timestamp":1789516683000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/35\/4941\/8744050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":56,"journal-issue":{"issue":"35","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag562","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,14]]},"published":{"date-parts":[[2026,7,28]]}}}